These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 27450464)

  • 1. Re: Consensus Guidelines for Reporting Prostate Cancer Gleason Grade: A. Zietman, E. Klein, M. J. Droller, P. Dasgupta, J. Catto and J. A. Smith, Jr. J Urol 2016;195: 1723.
    Egevad L; Samaratunga H; Srigley JR; Delahunt B
    J Urol; 2016 Oct; 196(4):1321-3. PubMed ID: 27450464
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Egevad L; Samaratunga H; Srigley JR; Delahunt B
    Eur Urol; 2017 Feb; 71(2):e52-e53. PubMed ID: 27460353
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Lars Egevad, Hemamali Samaratunga, John R. Srigley, Brett Delahunt's Letter to the Editor re: Anthony Zietman, Joseph Smith, Eric Klein, Michael Droller, Prokar Dasgupta, James Catto. Describing the Grade of Prostate Cancer: Consistent Use of Contemporary Terminology Is Now Required. Eur Urol 2016;70:1.
    Zietman A; Smith J; Klein E; Droller M; Dasgupta P; Catto J
    Eur Urol; 2017 Feb; 71(2):e54. PubMed ID: 27452952
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply by Anthony Zietman, Eric Klein, Michael J. Droller, Prokar Dasgupta, James Catto and Joseph A. Smith, Jr.
    J Urol; 2016 Oct; 196(4):1322-3. PubMed ID: 27450463
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 6. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
    Epstein JI; Egevad L; Amin MB; Delahunt B; Srigley JR; Humphrey PA;
    Am J Surg Pathol; 2016 Feb; 40(2):244-52. PubMed ID: 26492179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Fankhauser CD; Mucci LA; Gerke TA
    Eur Urol; 2017 Jul; 72(1):e9-e10. PubMed ID: 28108146
    [No Abstract]   [Full Text] [Related]  

  • 8. International Society of Urological Pathology (ISUP) grading of prostate cancer - An ISUP consensus on contemporary grading.
    Egevad L; Delahunt B; Srigley JR; Samaratunga H
    APMIS; 2016 Jun; 124(6):433-5. PubMed ID: 27150257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.
    Epstein JI; Amin MB; Reuter VE; Humphrey PA
    Am J Surg Pathol; 2017 Apr; 41(4):e1-e7. PubMed ID: 28177964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consensus guidelines for reporting prostate cancer Gleason Grade.
    Egevad L; Samaratunga H; Srigley JR; Delahunt B; Zietman A; Smith J; Klein E; Droller M; Dasgupta P; Catto J
    BJU Int; 2016 Sep; 118(3):E1-2. PubMed ID: 27524719
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: Alessandro Morlacco, John C. Cheville, Laureano J. Rangel, Derek J. Gearman, R. Jeffrey Karnes. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-risk" Prostate Cancer: Implications for Active Surveillance. Eur Urol 2017;72:442-7.
    Du C; Chen H; Li C
    Eur Urol; 2017 Nov; 72(5):e125. PubMed ID: 28169017
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Christian Daniel Fankhauser, Lorelei A. Mucci, and Travis A. Gerke's Letter to the Editor re: Won Sik Ham, Heather J. Chalfin, Zhaoyong Feng, et al. New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8-10 Prostate Cancer. Eur Urol 2017;71:907-12.
    Epstein JI; Trock B; Han M
    Eur Urol; 2017 Jul; 72(1):e11-e12. PubMed ID: 28108147
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Small prostate size and high grade disease--biology or artifact?: J. J. Liu, J. D. Brooks, M. Ferrari, R. Nolley and J. C. Presti, Jr. J Urol 2011; 185: 2108-2111.
    Calışkan S
    J Urol; 2011 Dec; 186(6):2504; author reply 2504-5. PubMed ID: 22019038
    [No Abstract]   [Full Text] [Related]  

  • 14. Consensus guidelines for reporting prostate cancer Gleason Grade.
    Zietman A; Smith J; Klein E; Droller M; Dasgupta P; Catto J
    BJU Int; 2016 Jun; 117(6):849. PubMed ID: 27173992
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006.
    Walsh PC
    J Urol; 2006 Dec; 176(6 Pt 1):2744; author reply 2744. PubMed ID: 17085206
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era: A. S. Kibel, J. P. Ciezki, E. A. Klein, C. A. Reddy, J. D. Lubahn, J. Haslag-minoff, J. O. Deasy, J. M. Michalski, D. Kallogjeri, J. F. Piccirillo, D. M. Rabah, C. Yu, M. W. Kattan And A. J. Stephenson; J Urol 2012; 187: 1259-1265.
    Stenmark MH; Hamstra DA
    J Urol; 2012 Dec; 188(6):2438-9; author reply 2439-40. PubMed ID: 23088984
    [No Abstract]   [Full Text] [Related]  

  • 19. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re: Factors predicting prostatic biopsy Gleason sum under grading: D. A. Stackhouse, L. Sun, F. R. Schroeck, J. Jayachandran, A. A. Caire, C. O. Acholo, C. N. Robertson, D. M. Albala, T. J. Polascik, C. F. Donatucci, K. E. Maloney and J. W. Moul J Urol 2009; 182: 118-124.
    Labanaris AP; Kühn R; Zugor V
    J Urol; 2010 Jan; 183(1):396-7; author reply 397-8. PubMed ID: 19945124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.